Related references
Note: Only part of the references are listed.Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)
Simon R. Sinclair et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist
Christopher A. Salvatore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
CGRP Receptor Antagonism and Migraine
Lars Edvinsson et al.
NEUROTHERAPEUTICS (2010)
Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus
Marie-Luise Sixt et al.
BRAIN (2009)
Origin of pain in migraine: evidence for peripheral sensitisation
Jes Olesen et al.
LANCET NEUROLOGY (2009)
Randomized, controlled trial of telcagepant for the acute treatment of migraine
K. M. Connor et al.
NEUROLOGY (2009)
CGRP blockers in migraine therapy: where do they act?
L. Edvinsson
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
T. W. Ho et al.
NEUROLOGY (2008)
Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-1-yl)piperidine-1-carboxamide], a potent and orally Active calcitonin gene-related peptide receptor antagonist for the treatment of migraine
Christopher A. Salvatore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Inhibitory effect of BIBN4096BS, CGRP8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery
L. Edvinsson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine
D Levy et al.
ANNALS OF NEUROLOGY (2005)
BIBN4096BS and CGRP8-37 antagonize the relaxant effects of α-CGRP more than those of β-CGRP in human extracranial arteries
R Verheggen et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat
RJ Storer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
BIBN4096BS is a potent competitive antagonist of the relaxant effects of α-CGRP on human temporal artery:: comparison with CGRP(8-37)
R Verheggen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells
L Edvinsson et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment
MJ Moreno et al.
NEUROPHARMACOLOGY (2002)
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
H Doods et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
